Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 3 of 3 entries
Sorted by: Best Match Show Resources per page
In vitro pharmacological characterization of a novel TRPA1 antagonist and proof of mechanism in a human dental pulp model.

Journal of pain research

Nyman E, Franzén B, Nolting A, Klement G, Liu G, Nilsson M, Rosén A, Björk C, Weigelt D, Wollberg P, Karila P, Raboisson P.
PMID: 23403691
J Pain Res. 2013;6:59-70. doi: 10.2147/JPR.S37567. Epub 2013 Jan 30.

AZ465 is a novel selective transient receptor potential cation channel, member A1 (TRPA1) antagonist identified during a focused drug discovery effort. In vitro, AZ465 fully inhibits activation by zinc, O-chlorobenzylidene malononitrile (CS), or cinnamaldehyde of the human TRPA1 channel...

Cite
Nyman E, Franzén B, Nolting A, et al. In vitro pharmacological characterization of a novel TRPA1 antagonist and proof of mechanism in a human dental pulp model. J Pain Res. 2013;6:59-70doi: 10.2147/JPR.S37567.
Nyman, E., Franzén, B., Nolting, A., Klement, G., Liu, G., Nilsson, M., Rosén, A., Björk, C., Weigelt, D., Wollberg, P., Karila, P., & Raboisson, P. (2013). In vitro pharmacological characterization of a novel TRPA1 antagonist and proof of mechanism in a human dental pulp model. Journal of pain research, 659-70. https://doi.org/10.2147/JPR.S37567
Nyman, Eva, et al. "In vitro pharmacological characterization of a novel TRPA1 antagonist and proof of mechanism in a human dental pulp model." Journal of pain research vol. 6 (2013): 59-70. doi: https://doi.org/10.2147/JPR.S37567
Nyman E, Franzén B, Nolting A, Klement G, Liu G, Nilsson M, Rosén A, Björk C, Weigelt D, Wollberg P, Karila P, Raboisson P. In vitro pharmacological characterization of a novel TRPA1 antagonist and proof of mechanism in a human dental pulp model. J Pain Res. 2013;6:59-70. doi: 10.2147/JPR.S37567. Epub 2013 Jan 30. PMID: 23403691; PMCID: PMC3565573.
Copy Download .nbib Format: NLM
Platelet protein biomarker panel for ovarian cancer diagnosis.

Biomarker research

Lomnytska M, Pinto R, Becker S, Engström U, Gustafsson S, Björklund C, Templin M, Bergstrand J, Xu L, Widengren J, Epstein E, Franzén B, Auer G.
PMID: 29344361
Biomark Res. 2018 Jan 12;6:2. doi: 10.1186/s40364-018-0118-y. eCollection 2018.

BACKGROUND: Platelets support cancer growth and spread making platelet proteins candidates in the search for biomarkers.METHODS: Two-dimensional (2D) gel electrophoresis, Partial Least Squares Discriminant Analysis (PLS-DA), Western blot, DigiWest.RESULTS: PLS-DA of platelet protein expression in 2D gels suggested differences...

Cite
Lomnytska M, Pinto R, Becker S, et al. Platelet protein biomarker panel for ovarian cancer diagnosis. Biomark Res. 2018;6:2doi: 10.1186/s40364-018-0118-y.
Lomnytska, M., Pinto, R., Becker, S., Engström, U., Gustafsson, S., Björklund, C., Templin, M., Bergstrand, J., Xu, L., Widengren, J., Epstein, E., Franzén, B., & Auer, G. (2018). Platelet protein biomarker panel for ovarian cancer diagnosis. Biomarker research, 62. https://doi.org/10.1186/s40364-018-0118-y
Lomnytska, Marta, et al. "Platelet protein biomarker panel for ovarian cancer diagnosis." Biomarker research vol. 6 (2018): 2. doi: https://doi.org/10.1186/s40364-018-0118-y
Lomnytska M, Pinto R, Becker S, Engström U, Gustafsson S, Björklund C, Templin M, Bergstrand J, Xu L, Widengren J, Epstein E, Franzén B, Auer G. Platelet protein biomarker panel for ovarian cancer diagnosis. Biomark Res. 2018 Jan 12;6:2. doi: 10.1186/s40364-018-0118-y. eCollection 2018. PMID: 29344361; PMCID: PMC5767003.
Copy Download .nbib Format: NLM
Multiplex immune protein profiling of fine-needle aspirates from patients with non-small-cell lung cancer reveals signatures associated with PD-L1 expression and tumor stage.

Molecular oncology

Franzén B, Viktorsson K, Kamali C, Darai-Ramqvist E, Grozman V, Arapi V, Hååg P, Kaminskyy VO, Hydbring P, Kanter L, Nyrén S, Ekman S, De Petris L, Lewensohn R.
PMID: 33768639
Mol Oncol. 2021 Nov;15(11):2941-2957. doi: 10.1002/1878-0261.12952. Epub 2021 May 01.

Biomarker signatures identified through minimally invasive procedures already at diagnosis of non-small-cell lung cancer (NSCLC) could help to guide treatment with immune checkpoint inhibitors (ICI). Here, we performed multiplex profiling of immune-related proteins in fine-needle aspirate (FNA) samples of...

Cite
Franzén B, Viktorsson K, Kamali C, et al. Multiplex immune protein profiling of fine-needle aspirates from patients with non-small-cell lung cancer reveals signatures associated with PD-L1 expression and tumor stage. Mol Oncol. 2021;15(11):2941-2957doi: 10.1002/1878-0261.12952.
Franzén, B., Viktorsson, K., Kamali, C., Darai-Ramqvist, E., Grozman, V., Arapi, V., Hååg, P., Kaminskyy, V. O., Hydbring, P., Kanter, L., Nyrén, S., Ekman, S., De Petris, L., & Lewensohn, R. (2021). Multiplex immune protein profiling of fine-needle aspirates from patients with non-small-cell lung cancer reveals signatures associated with PD-L1 expression and tumor stage. Molecular oncology, 15(11), 2941-2957. https://doi.org/10.1002/1878-0261.12952
Franzén, Bo, et al. "Multiplex immune protein profiling of fine-needle aspirates from patients with non-small-cell lung cancer reveals signatures associated with PD-L1 expression and tumor stage." Molecular oncology vol. 15,11 (2021): 2941-2957. doi: https://doi.org/10.1002/1878-0261.12952
Franzén B, Viktorsson K, Kamali C, Darai-Ramqvist E, Grozman V, Arapi V, Hååg P, Kaminskyy VO, Hydbring P, Kanter L, Nyrén S, Ekman S, De Petris L, Lewensohn R. Multiplex immune protein profiling of fine-needle aspirates from patients with non-small-cell lung cancer reveals signatures associated with PD-L1 expression and tumor stage. Mol Oncol. 2021 Nov;15(11):2941-2957. doi: 10.1002/1878-0261.12952. Epub 2021 May 01. PMID: 33768639; PMCID: PMC8564641.
Copy Download .nbib Format: NLM
Showing 1 to 3 of 3 entries